



Press Release

Orexo Completes Bond Buyback Program

Uppsala, Sweden – December 21, 2016 – Orexo AB (publ.) announces that it has successfully completed a bond buyback program and in total purchased Orexo corporate bonds in the market with a nominal value of MSEK 99. The program was initiated on December 13, 2016, and completed by December 20, 2016. After the purchase the new bond balance is MSEK 401.

Pareto Securities and Danske Bank assisted Orexo in this process.

For more information please contact:

Orexo AB (publ.)

Henrik Juuel, EVP and CFO

Tel: +46 18 780 88 00

Email: ir@orexo.com

Lena Wange, IR & Communications Manager

Tel: +46 18 780 88 00

Email: ir@orexo.com

About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo's unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo's share is listed on Nasdaq Stockholm Exchange Mid Cap (STO:ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo's global headquarters and R&D are based in Uppsala, Sweden.

For more information about Orexo, please visit www.orexo.com or follow us on [Twitter](#) or [LinkedIn](#). For further information about Zubsolv in the US, please visit www.zubsolv.com.

The information was submitted for publication at 8:00am CET, December 21, 2016